Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-12-19 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price for convertible bonds (CB) due to market price fluctuations. This type of filing is a standard corporate action related to capital structure and financial instruments, specifically categorized as a 'Share Issue/Capital Change' (SHA) in many financial databases, as it directly impacts the potential number of shares to be issued upon conversion.
2023-12-19 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the exercise price for its outstanding bond with warrants (BW). This type of disclosure, which details changes to the conversion or exercise price of equity-linked securities due to market price fluctuations, is classified under 'Capital/Financing Update' (CAP) as it directly relates to the company's capital structure and financing instruments.
2023-12-15 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samil Pharmaceutical Co., Ltd. for the third quarter of 2023. It contains detailed financial statements, business descriptions, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the exchange price for convertible bonds (exchangeable bonds) due to a decline in the market price of the underlying stock. This type of filing, which details changes to capital structure instruments like convertible or exchangeable securities, falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but rather a specific disclosure of a financial event affecting the company's capital structure.
2023-10-30 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares and convertible securities by Susung Asset Management and its special related parties in Samil Pharmaceutical. This falls under the category of Major Shareholding Notification as it tracks changes in significant ownership levels.
2023-09-04 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for Samil Pharmaceutical Co., Ltd. for the period ending June 30, 2023. It contains comprehensive financial statements, management discussion and analysis, and corporate governance details, which are characteristic of an interim financial report. It is not a mere announcement or certification, as it includes detailed financial data, tables, and operational information. H1 2023
2023-08-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.